These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 20824052)
1. Labeling of oxidizable proteins with a photoactivatable analog of the antitumor agent DMXAA: evidence for redox signaling in its mode of action. Brauer R; Wang LC; Woon ST; Bridewell DJ; Henare K; Malinger D; Palmer BD; Vogel SN; Kieda C; Tijono SM; Ching LM Neoplasia; 2010 Sep; 12(9):755-65. PubMed ID: 20824052 [TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological activity of azido analogues of 5,6-dimethylxanthenone-4-acetic acid for use in photoaffinity labeling. Palmer BD; Henare K; Woon ST; Sutherland R; Reddy C; Wang LC; Kieda C; Ching LM J Med Chem; 2007 Aug; 50(16):3757-64. PubMed ID: 17616114 [TBL] [Abstract][Full Text] [Related]
3. Proteomic response to 5,6-dimethylxanthenone 4-acetic acid (DMXAA, vadimezan) in human non-small cell lung cancer A549 cells determined by the stable-isotope labeling by amino acids in cell culture (SILAC) approach. Pan ST; Zhou ZW; He ZX; Zhang X; Yang T; Yang YX; Wang D; Qiu JX; Zhou SF Drug Des Devel Ther; 2015; 9():937-68. PubMed ID: 25733813 [TBL] [Abstract][Full Text] [Related]
4. Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cao Z; Baguley BC; Ching LM Cancer Res; 2001 Feb; 61(4):1517-21. PubMed ID: 11245459 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of DMXAA-induced tumor necrosis factor production in murine splenocyte cultures by NF-kappaB inhibitors. Wang LC; Woon ST; Baguley BC; Ching LM Oncol Res; 2006; 16(1):1-14. PubMed ID: 16783963 [TBL] [Abstract][Full Text] [Related]
6. p38 mitogen-activated protein kinase is required for the antitumor activity of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid. Wu Q; Quan H; Xu Y; Li Y; Hu Y; Lou L J Pharmacol Exp Ther; 2012 Jun; 341(3):709-17. PubMed ID: 22414857 [TBL] [Abstract][Full Text] [Related]
7. Induction of tumour necrosis factor and interferon-gamma in cultured murine splenocytes by the antivascular agent DMXAA and its metabolites. Wang LC; Reddy CB; Baguley BC; Kestell P; Sutherland R; Ching LM Biochem Pharmacol; 2004 Mar; 67(5):937-45. PubMed ID: 15104247 [TBL] [Abstract][Full Text] [Related]
8. Tumor vascular response to photodynamic therapy and the antivascular agent 5,6-dimethylxanthenone-4-acetic acid: implications for combination therapy. Seshadri M; Spernyak JA; Mazurchuk R; Camacho SH; Oseroff AR; Cheney RT; Bellnier DA Clin Cancer Res; 2005 Jun; 11(11):4241-50. PubMed ID: 15930363 [TBL] [Abstract][Full Text] [Related]
9. Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice. Ching LM; Goldsmith D; Joseph WR; Körner H; Sedgwick JD; Baguley BC Cancer Res; 1999 Jul; 59(14):3304-7. PubMed ID: 10416582 [TBL] [Abstract][Full Text] [Related]
10. Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy. Joseph WR; Cao Z; Mountjoy KG; Marshall ES; Baguley BC; Ching LM Cancer Res; 1999 Feb; 59(3):633-8. PubMed ID: 9973211 [TBL] [Abstract][Full Text] [Related]
12. Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid. Cao Z; Joseph WR; Browne WL; Mountjoy KG; Palmer BD; Baguley BC; Ching LM Br J Cancer; 1999 May; 80(5-6):716-23. PubMed ID: 10360649 [TBL] [Abstract][Full Text] [Related]
13. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma. Jassar AS; Suzuki E; Kapoor V; Sun J; Silverberg MB; Cheung L; Burdick MD; Strieter RM; Ching LM; Kaiser LR; Albelda SM Cancer Res; 2005 Dec; 65(24):11752-61. PubMed ID: 16357188 [TBL] [Abstract][Full Text] [Related]
14. A comparison of the ability of DMXAA and xanthenone analogues to activate NF-kappaB in murine and human cell lines. Woon ST; Reddy CB; Drummond CJ; Schooltink MA; Baguley BC; Kieda C; Ching LM Oncol Res; 2005; 15(7-8):351-64. PubMed ID: 16491953 [TBL] [Abstract][Full Text] [Related]
15. Vascular disrupting agent drug classes differ in effects on the cytoskeleton. Kim S; Peshkin L; Mitchison TJ PLoS One; 2012; 7(7):e40177. PubMed ID: 22848372 [TBL] [Abstract][Full Text] [Related]
16. Efficacy against subcutaneous or intracranial murine GL261 gliomas in relation to the concentration of the vascular-disrupting agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), in the brain and plasma. Yung R; Seyfoddin V; Guise C; Tijono S; McGregor A; Connor B; Ching LM Cancer Chemother Pharmacol; 2014 Mar; 73(3):639-49. PubMed ID: 24477604 [TBL] [Abstract][Full Text] [Related]
17. Neutrophil influx and chemokine production during the early phases of the antitumor response to the vascular disrupting agent DMXAA (ASA404). Wang LC; Thomsen L; Sutherland R; Reddy CB; Tijono SM; Chen CJ; Angel CE; Dunbar PR; Ching LM Neoplasia; 2009 Aug; 11(8):793-803. PubMed ID: 19649209 [TBL] [Abstract][Full Text] [Related]
18. 5,6-Dimethylxanthenone-4-acetic acid (DMXAA) activates stimulator of interferon gene (STING)-dependent innate immune pathways and is regulated by mitochondrial membrane potential. Prantner D; Perkins DJ; Lai W; Williams MS; Sharma S; Fitzgerald KA; Vogel SN J Biol Chem; 2012 Nov; 287(47):39776-88. PubMed ID: 23027866 [TBL] [Abstract][Full Text] [Related]
19. Tumor vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Suppresses macrophage capping protein beyond STING activation. Xiao Z; Cui X; Liu F; Wang Y; Liu X; Zhou W; Zhang Y Biochim Biophys Acta Mol Basis Dis; 2024 Jun; 1870(5):167149. PubMed ID: 38565383 [TBL] [Abstract][Full Text] [Related]